What the Ozempic Label Says About Gastroparesis: A Research Update
Latest update (2026-01)
- FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Information to Targeted Risk Awareness
If you've experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering if the medication could be causing gastroparesis. Decades of pharmacovigilance have established a framework for identifying and reporting medication side effects, and recent label updates now formally acknowledge this risk. This article reviews the FDA label changes and what they mean for patients.
Ozempic and Gastrointestinal Adverse Reactions: Clinical Evidence
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal reactions are prominent and have been documented in clinical trials. In placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Understanding Gastroparesis and Its Link to Ozempic
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation can vary from mild discomfort to severe malnutrition and dehydration. Diagnosis typically involves gastric emptying scintigraphy or breath tests. The mechanistic pathways linking Ozempic to gastroparesis are rooted in its pharmacology as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and activation slows gastric motility and emptying. This effect is intended to reduce postprandial glucose excursions but can become pathological, leading to gastroparesis-like symptoms. The label for Ozempic lists gastrointestinal adverse reactions with a frequency of less than 5%, including dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed as a separate adverse reaction in these data, the constellation of symptoms—particularly nausea, vomiting, dyspepsia, and gastroesophageal reflux—overlaps with gastroparesis presentation.
Risk Assessment and Legal Considerations for Settlement
Risk assessment for patients considering Ozempic must weigh the adequacy of warnings regarding gastroparesis. The label does not include a specific warning for gastroparesis, but it does caution about gastrointestinal adverse reactions and notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a dedicated gastroparesis warning may affect informed consent and patient awareness. For affected patients, settlement-related considerations hinge on establishing a causal link between Ozempic exposure and the development of gastroparesis. Key factors include the timeline between exposure and documented harm. Clinical trial data show that gastrointestinal adverse reactions often occur during dose escalation, suggesting that early exposure is a critical period. However, gastroparesis may develop or persist after prolonged use. Patients who experience severe, persistent gastrointestinal symptoms after starting Ozempic should be evaluated for gastroparesis. Documentation of symptom onset relative to drug initiation, diagnostic test results, and exclusion of other causes are essential for legal claims. In summary, Ozempic is associated with a higher incidence of gastrointestinal adverse reactions compared to placebo, and its pharmacological effect on gastric motility provides a plausible mechanism for gastroparesis. The label does not specifically warn about gastroparesis, which may be a point of contention in litigation. Patients who develop gastroparesis after Ozempic use should seek medical evaluation and legal counsel to assess eligibility for settlement based on individual circumstances.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the link between Ozempic and gastroparesis?
Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric motility as part of its mechanism. Clinical trials show a higher incidence of gastrointestinal adverse reactions, including nausea, vomiting, dyspepsia, and gastroesophageal reflux, which overlap with gastroparesis symptoms. While gastroparesis is not explicitly listed as a separate adverse reaction, the pharmacological effect provides a plausible mechanism for its development.
What are the criteria for an Ozempic gastroparesis lawsuit settlement?
Settlement eligibility typically requires documented Ozempic exposure, a confirmed gastroparesis diagnosis via gastric emptying scintigraphy or breath tests, and evidence of a temporal relationship between drug initiation and symptom onset. Exclusion of other causes of gastroparesis (e.g., diabetes, surgery) is also important. Legal counsel can assess individual cases.
Does the Ozempic label warn about gastroparesis?
No, the label does not include a specific warning for gastroparesis. It does caution about gastrointestinal adverse reactions and serious hypersensitivity reactions. The absence of a dedicated gastroparesis warning may be a point of contention in litigation regarding informed consent.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.